PICAROS - Acalabrutinib RWE on 1L CLL in Spain
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci w wieku 18 lat lub starsi.
- •Zdiagnozowana przewlekła białaczka limfocytowa (CLL).
- •Rozpoczęcie leczenia acalabrutynibem w pierwszym rzucie terapii w ciągu roku przed wizytą.
- •Pacjenci otrzymujący acalabrutynib samodzielnie lub w połączeniu z wenetoklaksem (z obinutuzumabem lub bez) w leczeniu pierwszego rzutu.
- •Decyzja o podaniu acalabrutynibu musi być podjęta i udokumentowana przed włączeniem do badania.
- •Pacjent musi wyrazić świadomą zgodę na udział w badaniu (jeśli żyje).
✗ Disqualifies
- •Pacjenci uczestniczący w innym badaniu klinicznym podczas leczenia acalabrutynibem.
- •Pacjenci, którzy nie rozumieją języka hiszpańskiego lub stanu swojego zdrowia, aby wziąć udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 28, 2026
- Sex
- No restrictions
Locations (49)
Research Site
Almería, Spain
Research Site
Córdoba, Spain
Research Site
Granada, Spain
Research Site
Jaén, Spain
Research Site
Marbella, Spain
Research Site
Málaga, Spain
Research Site
Seville, Spain
Research Site
Zaragoza, Spain
Research Site
Palma de Mallorca, Spain
Research Site
Palma de Mallorca, Spain
Research Site
Donostia / San Sebastian, Spain
Research Site
Galdakao, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
San Cristóbal de La Laguna, Spain
Research Site
Santander, Spain
Research Site
Salamanca, Spain
Research Site
Segovia, Spain
Research Site
Valladolid, Spain
Research Site
Valladolid, Spain
Research Site
Guadalajara, Spain
Research Site
Toledo, Spain
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Granollers, Spain
Research Site
L'Hospitalet de Llobregat, Spain
Research Site
Lleida, Spain
Research Site
Terrassa, Spain
Research Site
Ourense, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Vigo, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Majadahonda, Spain
Research Site
El Palmar, Spain
Research Site
Murcia, Spain
Research Site
Oviedo, Spain
Research Site
Alicante, Spain
Research Site
Valencia, Spain
Research Site
Valencia, Spain
Research Site
Valencia, Spain
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.